Abstract 898P
Background
Oral mucositis (OM) is severe in up to 70% of patients receiving standard chemoradiation (7 weeks of RT and concurrent cisplatin). Cisplatin contributes to the acute toxicity (acute kidney injury, tinnitus, myelosuppression) during treatment but also causes irreversible chronic kidney disease (CKD) in up to 30% of patients in the years following treatment. Two randomized, placebo-controlled, blinded studies, ROMAN (NCT03689712) and GT-201 (NCT02508389), evaluated avasopasem 90mg (AVA) for the reduction of severe OM (SOM, WHO grade 3-4) and both met their primary endpoints.
Methods
The ROMAN phase 3 (ITT N=407) and GT-201 phase 2b trials (ITT placebo and 90 mg N=144) results were aggregated using conventional methods for fixed-effects meta-analysis. In ROMAN, prospectively defined follow-up of serum creatinine (sCr) and estimated glomerular filtration rates (eGFR) were assessed every 3 months for 1 year following 7 weeks of CRT.
Results
The meta-analysis of ROMAN and GT-201 (N=551 [313 AVA/238 PBO]) showed a 19% relative reduction in SOM incidence (52% vs 64%; P=0.0053), 58% relative reduction in SOM duration (median, 8 vs 19 days; P=0.0002), 32% reduction in Grade 4 incidence (22% vs 32%; P=0.0102), and 28% delay in median days to SOM onset (median 50 vs 39 days; P=0.0005). Adverse event frequencies were mostly comparable between treatment groups with a trend towards reduction of certain IMRT- and cisplatin-related toxicities including tinnitus which was reported less with AVA in both studies. At 1-year follow-up, AVA was associated with significant improvements in preservation of eGFR (P=0.0008) and sCr (P=0.006) levels vs PBO. Grade 3+ CKD results through 12 months show 10% AVA vs 20% PBO (relative risk 0.55, P=0.0043).
Conclusions
AVA produced statistically significant, clinically meaningful improvement of SOM vs PBO that was consistent across multiple measures of SOM, with an adverse event profile consistent with expectations for IMRT/cisplatin. At 1-year follow-up, AVA appears to reduce cisplatin-related CKD in the study population.
Clinical trial identification
GTI-4419-301, 13 July 2020 (NCT03689712).
Editorial acknowledgement
Editorial (Sarah Hummasti, PhD) was provided by AOIC, LLC and funded by Galera Therapeutics, Inc.
Legal entity responsible for the study
Galera Therapeutics, Inc.
Funding
Galera Therapeutics, Inc.
Disclosure
N. Dunlap: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca. C. Anderson: Non-Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Galera Therapeutics, Inc. C. Lee: Financial Interests, Personal and Institutional, Research Funding: Bayer, Merck, Decipher Genetics; Financial Interests, Personal and Institutional, Advisory Role: Bayer, Merck, Decipher Genetics; Financial Interests, Personal, Stocks or ownership: Axcend LLC, Kobold Medical LLC. J. Kelley: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. G. Walker: Financial Interests, Personal, Advisory Role: Galera Therapeutics, Inc.; Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. V. Bar-Ad: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. D. Miller: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. V. King: Financial Interests, Personal, Ownership Interest: San Juan Cancer Center; Financial Interests, Personal, Leadership Role: San Juan Cancer Center. A. Peddada: Financial Interests, Personal, Stocks/Shares: Galera Therapeutics, Inc. D. Ciuba: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. F. Vincent: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. B. Muzyka: Financial Interests, Institutional, Research Funding: Galera Therapeutics, Inc. A. Gillespie-Twardy: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. S. Sonis: Financial Interests, Personal, Full or part-time Employment: Primary Endpoint Solutions ; Financial Interests, Personal, Leadership Role: Primary Endpoint Solutions ; Financial Interests, Institutional, Other, Contract work for study: Galera Therapeutics, Inc. E. Kennedy: Financial Interests, Personal, Full or part-time Employment: Galera Therapeutics, Inc.; Financial Interests, Personal, Stocks or ownership: Galera Therapeutics, Inc. D. Saunders: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12